Tampa, Florida and Montreal, Quebec, June 21, 2007 – UTEK Corporation (AMEX & LSE-AIM: UTK), a specialty finance company focused on technology transfer, and Haemacure Corporation (TSX: HAE), a specialty bio-therapeutics company developing high-value human proteins, today announced the signing of a technology acquisition alliance.
“Haemacure is pleased to execute this technology acquisition alliance with UTEK as we believe that it will provide Haemacure with global access to intellectual properties that can leverage our product candidates,” said Joseph Galli, Chief Executive Officer of Haemacure.
“UTEK looks forward to working with Haemacure to identify potential technology acquisition opportunities that fit its strategic vision. This alliance was entered into under UTEK’s previously announced Master Alliance Agreement with Rodman & Renshaw’s Acumen Biofin division,” commented Clifford Gross, Ph.D., Chief Executive Officer of UTEK.
Through its technology acquisition alliances, UTEK assists companies in enhancing their new product pipeline with the acquisition of proprietary intellectual capital from universities and laboratory research centers. Technology acquisition alliances are generally cancellable by either party with thirty days advance written notice.
About Haemacure Corporation
Haemacure Corporation is a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure’s research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats.
Hemaseel™HMN, Haemacure’s lead product candidate, is a human-derived fibrin sealant in late-stage clinical development. Haemacure’s second product candidate is human thrombin, a component of its fibrin sealant. Both candidates have applications in the expanding bio-surgical market. Follow-on development will focus on surgical haemostats, biomaterial combinations and drug delivery in select therapeutic areas. Haemacure has recently discovered additional specialty proteins in its plasma-derived intermediates and will advance these specialty proteins through partnerships with other pharmaceutical and biotechnology companies. For more information about Haemacure please visit its website at www.haemacure.com.
About UTEK Corporation
UTEK® is a specialty finance company focused on technology transfer. UTEK’s services enable companies to acquire innovative technologies from universities and research laboratories worldwide. UTEK facilitates the identification and acquisition of external technologies for clients in exchange for their equity securities. This unique process is called U2B®. In addition, UTEK offers companies the tools to search and analyze university intellectual properties. UTEK is a business development company with operations in the United States, United Kingdom and Israel. For more information about UTEK, please visit its website at www.utekcorp.com.
Forward-looking Statements
Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure Corporation does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure Corporation disclaims any intention or obligation to update these statements.
Contacts:
UTEK Corporation
USA:
Tania Bernier
Tel. : 813-754-4330 x 223
UK:
Bankside Consultants
Steve Liebmann or Simon Bloomfield
Tel.: + 44 (0) 20-7367-8883
Haemacure Corporation
Joseph Galli
Chairman and CEO
Tel. : 514-990-7074
Gilles Lemieux
Investor Relations
Tel. : 514-282-3350 ext. 22
Cel. : 514-968-1382
